Our Difference

Schedule Your Consultation +1-855-560-HEAL
Rehealth’s
DIFFERENCE.
At Rehealth, we are redefining regenerative medicine by combining cutting-edge science, unparalleled quality, and a patient-first approach. Our in-house laboratory allow us to maintain full control over the entire process, and our licensed technology is the focus of multiple U.S. clinical trials, ensuring a full safety profile and our dedication to efficacy and transparency for every patient.
What Sets
REHEALTH APART.

Superior Viability & Potency

We use a patented harvesting and expansion process that preserves cell purity, potency, and therapeutic value. By using Umbilical Cord Lining Stem Cells, the most potent and youthful form of Mesenchymal Stem Cell, our stem cells maintain optimal function and performance. This results in highly reliable regenerative outcomes, giving every patient consistent treatment quality and maximized healing potential with each and every application.

Exclusive In-House Laboratory

Unlike many providers, we operate our own laboratory. This gives us full oversight from harvesting through expansion and final quality checks. Our team controls every phase of production, ensuring unmatched safety and standardization. This dedication to quality helps every patient receive the highest level of care, with no compromise at any stage.

No Risk of Immune Rejection

Our stem cells lack the HLA-DR antigen, meaning they are immunologically silent and won’t trigger an immune reaction. This feature makes them universally compatible across patients. By eliminating the risk of rejection, we ensure greater treatment and broader regenerative potential supporting patients regardless of immune system status or medical background.

Proven Science. Trusted Tech

Rehealth uses U.S.-licensed technology backed by 15+ years of clinical research. With over $45 million invested in cellular development, we remain at the forefront of regenerative science. Our stem cells are also used in multiple U.S. clinical trials, further validating their safety and therapeutic value through data-driven evidence and consistent, successful outcomes.

Transparent. Tailored.

We believe in transparency and patient empowerment at every step. Each patient receives a personalized report showing the quality and potency of their stem cells. This ensures complete clarity and confidence in your treatment. Our tailored process gives every individual full insight and control—because real healing starts with understanding and trust.

At Rehealth, we are not just providers—we are pioneers in regenerative medicine, delivering next-level stem cell therapies with a focus on quality, innovation, and results.

Pioneering The Future with Advanced Therapies

With state-of-the-art facilities and proprietary stem cell, NK cell, and exosome treatments, Rehealth ensures precision, safety, and exceptional patient outcomes.
Schedule Your Consultation +1-855-560-HEAL

Proven Success

Over 1,500 patients have successfully completed treatment at Rehealth with life-changing results.

Success Rate

Rehealth therapies achieve a 90% success rate in improving quality of life for autoimmune patients.

Noticeable Improvements

Patients report significant symptom relief within 7 days of starting treatment at Rehealth.

Therapies
ELITE CARE.

Stem Cell Therapy

Activate your body’s natural ability to restore damaged tissues.
Learn More

Natural Killer Cells

Strengthen your immunity through targeted destruction of harmful cells.
Learn More

Exosome Therapy

Enhance cellular repair and regeneration with advanced exosome therapy.
Learn More
Our 6-step
STEM CELL PROCESS.

Donor Screening

All donors undergo comprehensive health evaluations to meet the highest medical standards. This step ensures that only the most qualified individuals contribute to the therapeutic cell lines we develop.

Viral Clearance

We screen all donors for viruses like EBV and CMV, which affect over 75% of people worldwide. Only virus-free, qualified donors are accepted to ensure purity, safety, and optimal therapeutic value.

ULSC Isolation

We isolate Umbilical Cord Lining Stem Cells (ULSCs) using proprietary growth protocols. This process maximizes potency and consistency while maintaining the effectiveness needed for regenerative treatment outcomes.

Chromosomal Testing

We assess genetic stability by growing and aging stem cells in controlled environments. This process helps identify and eliminate any potential chromosomal abnormalities before the cells are used in treatment.

Cell Profiling

Each stem cell batch undergoes testing for growth curve, size, viability, potency, and marker expression. This rigorous process ensures only the most consistent and therapeutically effective cells are selected for clinical use.

Sterility & Safety

We follow FDA-required sterility guidelines for all cellular therapeutics. Only the top two cell lines pass our quality checks—ensuring safety, consistency, and effectiveness in every clinical application.
Treatment
PROCESS.
1
Initial Consultation
We provide a tailored health assessment to understand your specific needs and goals.
2
Pre-Treatment
Our team supports you with preparation and travel logistics to ensure a seamless experience.
3
Treatment
Receive cutting-edge stem cell, NK cell, or exosome therapy at our state-of-the-art facility.
4
Post-Treatment
Comprehensive recovery guidance and follow-up care to monitor your progress and ensure results.
  1. Omar et al., 2014. Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies?  Tissue Eng Part B Rev. Oct;20(5):523-44.
  2. Jin Jin et al., 2013. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci Sep 3;14(9):17986-8001. 
  3. V de Oliveira et al., 2015. Bone marrow mesenchymal stromal cells isolated from multiple sclerosis patients have distinct gene expression profile and decreased suppressive function compared with healthy counterparts. Cell Transplant. 24(2):151-65e tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci Sep 3;14(9):17986-8001.